Show channels:
All channels
Bladder cancer
Brain and spinal
Breast cancer
Cervical
Colon & rectal
Dermatological
General Information
Gynecological
Head and Neck
Kidney/adrenal
Liver
Lung
Lymphoma
Multiple Myeloma
Myelodysplastic syndromes
Myeloproliferative disorders
Pancreas
Pediatric
Prostate
Sarcoma
Stomach
Testicular
Thyroid
Upper aerodigestive
Found 15757 articles
Lymphocyte antigen 6G6D-mediated modulation through p38α MAPK and DNA methylation in colorectal cancer
Lymphocyte antigen 6G6D universally downregulated in mucinous CRC.
»
08/11/22
Assessing the impact of MRI based diagnostics on pre-treatment disease classification and prognostic model performance in men diagnosed with new prostate cancer from an unscreened population
MRI guided diagnostics does change pre-treatment risk groups assignments.
»
08/11/22
Evaluation of the role of KPNA2 mutations in breast cancer prognosis using bioinformatics datasets
Aberrant KPNA2 overexpression directly correlated with poor patient prognosis.
»
08/10/22
Apoptosis and autophagy markers predict survival in neoadjuvant treated oesophageal adenocarcinoma patients
Patients who showed low/negative cleaved caspase-3 staining and high/positive staining for LC3B had worst overall survival.
»
08/20/22
Artichoke phytocomplex modulates serum microRNAs in patients exposed to asbestos: a first step of a phase II clinical trial
AWPC intake modulated 11 serum miRNAs related to gene-pathways connected to mesothelioma.
»
08/20/22
Inhibition of melanoma cell-intrinsic Tim-3 stimulates MAPK-dependent tumorigenesis.
MAPK targeting as combination strategy for circumventing adverse consequences of unintended melanoma-Tim-3 inhibition.
»
08/11/22
Risk of prostate cancer and death after benign transurethral resection of the prostate-A 20-year population-based analysis.
Men with low PSA levels and benign TURP can be reassured about their cancer risk.
»
06/27/22
Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC.
Characterization of four novel EML4-ALK-positive NSCLC cell lines.
»
04/26/22
Prognostic factors among patients with brain metastases from cancer of unknown primary site.
Incidence of patients with BM-CUPs steadily increasing over time.
»
07/01/22
Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial.
Overall survival (OS) did not differ between patients.
»
07/23/21
< Prev
Next >